Nivolumab-Based Regimens for Esophageal Squamous Cell Carcinoma

home / approval-alert / nivolumab-based-regimens-for-esophageal-squamous-cell-carcinoma

Nivolumab-Based Regimens for Esophageal Squamous Cell Carcinoma

In May 2022, nivolumab plus chemotherapy and nivolumab plus ipilimumab was approved by the FDA as a treatment for patients with unresectable advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 expression.

Articles
FDA Approves Nivolumab/Chemo and Nivolumab/Ipilimumab for Unresectable Advanced ESCC

FDA Approves Nivolumab/Chemo and Nivolumab/Ipilimumab for Unresectable Advanced ESCC

May 31st 2022

The FDA has granted approval to nivolumab plus ipilimumab and nivolumab plus chemotherapy for patients with unresectable advanced or metastatic esophageal squamous cell carcinoma.

Videos
Jaffer A. Ajani, MD, Discusses the Approval of Nivolumab Combinations in Esophageal Squamous Cell Carcinoma

Jaffer A. Ajani, MD, Discusses the Approval of Nivolumab Combinations in Esophageal Squamous Cell Carcinoma

May 31st 2022

Jaffer A. Ajani, MD, spoke about the recent approvals of nivolumab plus ipilimumab and nivolumab plus chemotherapy for patients with esophageal squamous cell carcinoma.